JP2023523584A5 - - Google Patents

Info

Publication number
JP2023523584A5
JP2023523584A5 JP2022564276A JP2022564276A JP2023523584A5 JP 2023523584 A5 JP2023523584 A5 JP 2023523584A5 JP 2022564276 A JP2022564276 A JP 2022564276A JP 2022564276 A JP2022564276 A JP 2022564276A JP 2023523584 A5 JP2023523584 A5 JP 2023523584A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
cancer
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523584A (ja
JP7791836B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028798 external-priority patent/WO2021216972A1/en
Publication of JP2023523584A publication Critical patent/JP2023523584A/ja
Publication of JP2023523584A5 publication Critical patent/JP2023523584A5/ja
Application granted granted Critical
Publication of JP7791836B2 publication Critical patent/JP7791836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564276A 2020-04-24 2021-04-23 抗ｃｄ３抗体及びその使用 Active JP7791836B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015149P 2020-04-24 2020-04-24
US63/015,149 2020-04-24
PCT/US2021/028798 WO2021216972A1 (en) 2020-04-24 2021-04-23 Anti-cd3 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023523584A JP2023523584A (ja) 2023-06-06
JP2023523584A5 true JP2023523584A5 (cg-RX-API-DMAC10.html) 2024-05-02
JP7791836B2 JP7791836B2 (ja) 2025-12-24

Family

ID=78270196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564276A Active JP7791836B2 (ja) 2020-04-24 2021-04-23 抗ｃｄ３抗体及びその使用

Country Status (6)

Country Link
US (1) US20230212289A1 (cg-RX-API-DMAC10.html)
EP (1) EP4139347A4 (cg-RX-API-DMAC10.html)
JP (1) JP7791836B2 (cg-RX-API-DMAC10.html)
CN (1) CN115803340A (cg-RX-API-DMAC10.html)
CA (1) CA3176391A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021216972A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
TWI877602B (zh) * 2022-04-21 2025-03-21 中央研究院 用於延長壽命及／或治療癌症的經基因工程化先天淋巴細胞
AU2023320486A1 (en) * 2022-08-04 2025-02-20 Memorial Hospital For Cancer And Allied Diseases Anti-cd24 antibodies and uses thereof
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
CN120958019A (zh) * 2023-03-29 2025-11-14 南京金斯瑞生物科技有限公司 针对人分化簇3蛋白的抗体及其变体
CN116574182B (zh) * 2023-06-09 2024-02-06 上海交通大学医学院附属第九人民医院 一种抗人Ki-67抗体及其制备方法和用途
CN121293363B (zh) * 2025-12-09 2026-04-21 上海玄言生物科技有限公司 一种靶向cd14和cd3的双功能t细胞衔接器及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465741B2 (en) * 2006-12-20 2013-06-18 Mmrglobal, Inc. Antibodies and methods for making and using them
CN102796199A (zh) * 2011-05-26 2012-11-28 中国医学科学院血液病医院 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途
EP2892924B1 (en) * 2012-06-14 2020-11-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
CN103173478B (zh) * 2013-03-04 2015-09-09 西北大学 一种携带ptd的抗人cd3单链抗体的制备方法
CN103467605B (zh) * 2013-09-05 2015-02-04 武汉友芝友生物制药有限公司 一种cd3抗原及其制备方法和用途
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
BR112017010793A2 (pt) * 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
WO2018237341A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
WO2019183266A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
US20220002398A1 (en) * 2018-06-07 2022-01-06 Oncoone Research & Development Gmbh ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
US20210277121A1 (en) * 2018-09-29 2021-09-09 Mab-Legend Biotech Co., Ltd. Dual targeting antigen binding molecule
CN110964114B (zh) * 2018-09-29 2023-07-04 上海博槿生物科技有限公司 一种双靶点抗原结合分子

Similar Documents

Publication Publication Date Title
Wei et al. ImmunoPET: concept, design, and applications
JP2022546572A5 (cg-RX-API-DMAC10.html)
Paul et al. Cancer therapy with antibodies
JP7235904B2 (ja) 抗ｉｌ１－ｒａｐ抗体
JP2024530166A5 (cg-RX-API-DMAC10.html)
Mandikian et al. Relative target affinities of T-cell–dependent bispecific antibodies determine biodistribution in a solid tumor mouse model
De Pauw et al. Current status and future expectations of nanobodies in oncology trials
Lamberts et al. Antibody positron emission tomography imaging in anticancer drug development
Bacac et al. A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
Welt et al. Phase I study of anticolon cancer humanized antibody A33
JP2022525435A5 (cg-RX-API-DMAC10.html)
Hernandez-Hoyos et al. MOR209/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer
JP2020523029A5 (cg-RX-API-DMAC10.html)
JP2023537002A5 (cg-RX-API-DMAC10.html)
Bailly et al. Pretargeting for imaging and therapy in oncological nuclear medicine
JP2022538117A5 (cg-RX-API-DMAC10.html)
IL273484B1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
Abousaway et al. Noninvasive imaging of cancer immunotherapy
Guo et al. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
WO2022216965A1 (en) Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells
Bogen et al. Treating bladder cancer: engineering of current and next generation antibody-, fusion protein-, mRNA-, cell-and viral-based therapeutics
JP2021517816A5 (cg-RX-API-DMAC10.html)
Lo et al. Anti-LYPD1/CD3 T-cell-dependent bispecific antibody for the treatment of ovarian cancer
Gao et al. Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer
Mulgaonkar et al. Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy